A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06188520 by AstraZeneca, with 564 participants planned, started 2023-12-05 and due to reach its primary completion in 2027-08-04. Interventions recorded: AZD8421, Camizestrant, Ribociclib, Palbociclib, Abemaciclib. Conditions listed: ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC). No results are recorded here; the registry entry is the source.